INCR Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

0.877

Open

0.850

VWAP

0.87

Vol

2.47K

Mkt Cap

48.00M

Low

0.840

Amount

2.14K

EV/EBITDA(TTM)

--

Total Shares

54.68M

EV

229.24M

EV/OCF(TTM)

--

P/S(TTM)

0.40

InterCure Ltd is an Israel-based company primarily enagged in cannabis industry. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.

Show More

Events Timeline

(ET)

2026-03-03

17:00:00

InterCure Receives Nasdaq Compliance Notice

2026-02-19 (ET)

2026-02-19

07:10:00

InterCure Expects Positive EBITDA for 2025

2025-11-03 (ET)

2025-11-03

08:38:59

InterCure and Cannasoul Forge Strategic Investment and Collaboration Partnerships

2025-10-08 (ET)

2025-10-08

09:03:28

InterCure Announces 1H Revenue of NIS 130M, Up from NIS 126M Last Year

2025-09-19 (ET)

2025-09-19

08:51:16

InterCure Reveals Purchase of ISHI for 4.92 Million Common Shares

2025-02-12 (ET)

2025-02-12

17:37:10

InterCure names Alexander Rabinovich as Chairman, replacing Ehud Barak

2024-12-20 (ET)

2024-12-20

07:36:21

InterCure secures funding to support recovery of Nir Oz facility

News

seekingalpha

05-01seekingalpha

InterCure Reports Significant FY Revenue Growth

Newsfilter

04-30Newsfilter

InterCure Reports Strong 2025 Financial Results with Positive Adjusted EBITDA

Yahoo Finance

03-03Yahoo Finance

InterCure Receives Noncompliance Notice from Nasdaq

seekingalpha

03-03seekingalpha

InterCure Receives Nasdaq Compliance Notice

Benzinga

2025-12-19Benzinga

Trump's Marijuana Reclassification Expected to Propel This Cannabis ETF: Significant Momentum Increase

Benzinga

2025-09-19Benzinga

InterCure Joins High-End US Cannabis Market Through ISHI Agreement

Valuation Metrics

The current forward P/E ratio for InterCure Ltd (INCR.O) is 6.18, compared to its 5-year average forward P/E of 0.20. For a more detailed relative valuation and DCF analysis to assess InterCure Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

0.20

Current PE

6.18

Overvalued PE

2.64

Undervalued PE

-2.23

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-0.52

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

11.78

Undervalued EV/EBITDA

-12.81

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

1.30

Current PS

0.00

Overvalued PS

2.30

Undervalued PS

0.30

Financials

AI Analysis

Annual

Quarterly

Whales Holding INCR

Trading Trends

People Also Watch

Frequently Asked Questions

What is InterCure Ltd (INCR) stock price today?

The current price of INCR is 0.877801 USD — it has increased 3.66

What is InterCure Ltd (INCR)'s business?

InterCure Ltd is an Israel-based company primarily enagged in cannabis industry. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.

What is the price predicton of INCR Stock?

Wall Street analysts forecast INCR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for INCR is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is InterCure Ltd (INCR)'s revenue for the last quarter?

InterCure Ltd revenue for the last quarter amounts to 102.44M USD, increased 7.52

What is InterCure Ltd (INCR)'s earnings per share (EPS) for the last quarter?

InterCure Ltd. EPS for the last quarter amounts to 0.10 USD, decreased -70.59

How many employees does InterCure Ltd (INCR). have?

InterCure Ltd (INCR) has 280 emplpoyees as of May 26 2026.

What is InterCure Ltd (INCR) market cap?

Today INCR has the market capitalization of 48.00M USD.